| Esther Good, MD | |
|
1215 Lee St., Mail Stop 800699, Charlottesville, VA 22908-0816 | |
| (434) 924-2231 | |
| (434) 924-9295 |
| Full Name | Esther Good |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Location | 1215 Lee St., Charlottesville, Virginia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1326676164 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 0101278868 (Virginia) | Primary |
| Entity Name | University Of Virginia Physicians Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033138250 PECOS PAC ID: 4880590728 Enrollment ID: O20040102000780 |
News Archive
Resverlogix Corp. announced today that it has officially activated the first site for the ASSURE 1 trial and commenced enrollment of patients for dosing of RVX-208. ASSURE 1 is the second Resverlogix Phase 2 clinical trial, led by Cleveland Clinic. This trial will examine RVX-208, Resverlogix's oral small molecule therapy for the treatment of atherosclerosis, in patients with acute coronary syndrome (ACS). This preparatory acute coronary syndrome study will ensure that 50 percent of the enrolled patients receive the IVUS (intravascular ultrasound) assessment.
Since its introduction in 2011, Bio-Rad Laboratory's Droplet Digital PCR (ddPCR-) technology has demonstrated the potential to be a transformative technology, particularly in clinical applications.
Kaiser Health News staff writers Julie Appleby and Kate Steadman write about the provisions in the health bill that will take effect soon. "Obama administration officials and wonks call them 'early deliverables.'
A common gut microbe could soon be offering us pain relief. Japanese bioengineers have tweaked Escherichia coli genes so that they pump out thebaine, a morphine precursor that can be modified to make painkillers. The genetically modified E. coli produces 300 times more thebaine with minimal risk of unregulated use compared to a recently developed method involving yeast.
The top executive of Wellpoint, a major health insurer, called for health reform at a meeting of the Economic Club in Indianapolis Tuesday, WTHR, the local NBC affiliate, reports. "The high and rising cost of health care in America is just not sustainable …" said CEO Angela Braly. Those costs pose "a real threat to the social and fiscal obligations of the government and to the health and prosperity of the American people."
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Esther Good, MD Po Box 9007, Charlottesville, VA 22906-9007 Ph: () - | Esther Good, MD 1215 Lee St., Mail Stop 800699, Charlottesville, VA 22908-0816 Ph: (434) 924-2231 |
News Archive
Resverlogix Corp. announced today that it has officially activated the first site for the ASSURE 1 trial and commenced enrollment of patients for dosing of RVX-208. ASSURE 1 is the second Resverlogix Phase 2 clinical trial, led by Cleveland Clinic. This trial will examine RVX-208, Resverlogix's oral small molecule therapy for the treatment of atherosclerosis, in patients with acute coronary syndrome (ACS). This preparatory acute coronary syndrome study will ensure that 50 percent of the enrolled patients receive the IVUS (intravascular ultrasound) assessment.
Since its introduction in 2011, Bio-Rad Laboratory's Droplet Digital PCR (ddPCR-) technology has demonstrated the potential to be a transformative technology, particularly in clinical applications.
Kaiser Health News staff writers Julie Appleby and Kate Steadman write about the provisions in the health bill that will take effect soon. "Obama administration officials and wonks call them 'early deliverables.'
A common gut microbe could soon be offering us pain relief. Japanese bioengineers have tweaked Escherichia coli genes so that they pump out thebaine, a morphine precursor that can be modified to make painkillers. The genetically modified E. coli produces 300 times more thebaine with minimal risk of unregulated use compared to a recently developed method involving yeast.
The top executive of Wellpoint, a major health insurer, called for health reform at a meeting of the Economic Club in Indianapolis Tuesday, WTHR, the local NBC affiliate, reports. "The high and rising cost of health care in America is just not sustainable …" said CEO Angela Braly. Those costs pose "a real threat to the social and fiscal obligations of the government and to the health and prosperity of the American people."
› Verified 7 days ago
Margaret K. Sande, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1215 Lee St, Charlottesville, VA 22908 Phone: 434-924-2231 Fax: 434-924-9295 | |
Aaron Frey, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1215 Lee St, Charlottesville, VA 22908 Phone: 434-924-2231 Fax: 434-924-9295 | |
Dr. Ursula Gailliot Koeze, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 459 Locust Ave, Mb 26, Charlottesville, VA 22902 Phone: 434-982-7150 Fax: 434-982-7147 | |
David R. Burt, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1215 Lee St, Charlottesville, VA 22908 Phone: 434-924-2231 Fax: 434-924-9295 | |
Mairin Smith, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 500 Martha Jefferson Dr, Charlottesville, VA 22911 Phone: 434-654-7154 | |
Avery Michienzi, Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1215 Lee St, Charlottesville, VA 22908 Phone: 434-924-2231 Fax: 434-924-9295 | |
John S. Huff, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1215 Lee St, Charlottesville, VA 22908 Phone: 434-924-2231 Fax: 434-924-9295 |